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Melatonin controls microbiota in 
colitis by goblet cell differentiation 
and antimicrobial peptide 
production through toll-like 
receptor 4 signalling
Seung Won Kim1,2,3, Soochan Kim1,3, Mijeong Son1,2,3, Jae Hee cheon1,2,3 & Young Sook park4*
Microbial dysbiosis has long been postulated to be associated with the pathogenesis of inflammatory 
bowel disease (IBD). Although evidence supporting the anti-colitic effects of melatonin have been 
accumulating, it is not clear how melatonin affects the microbiota. Herein, we investigated the effects 
of melatonin on the microbiome in colitis and identified involvement of Toll-like receptor (TLR) 4 
signalling in the effects. Melatonin improved dextran sulfate sodium (DSS)-induced colitis and reverted 
microbial dysbiosis in wild-type (WT) mice but not in TLR4 knockout (KO) mice. Induction of goblet cells 
was observed with melatonin administration, which was accompanied by suppression of Il1b and Il17a 
and induction of melatonin receptor and Reg3β, an antimicrobial peptide (AMP) against Gram-negative 
bacteria. In vitro, melatonin treatment of HT-29 intestinal epithelial cells promotes mucin and wound 
healing and inhibits growth of Escherichia coli. Herein, we showed that melatonin significantly increases 
goblet cells, Reg3β, and the ratio of Firmicutes to Bacteriodetes by suppressing Gram-negative bacteria 
through TLR4 signalling. Our study suggests that sensing of bacteria through TLR4 and regulation 
of bacteria through altered goblet cells and AMPs is involved in the anti-colitic effects of melatonin. 
Melatonin may have use in therapeutics for iBD.
Inflammatory bowel disease (IBD) is a chronic relapsing disorder of the gastrointestinal (GI) tract1 that results 
in chronic diarrhoea, abdominal pain, weight loss, and altered gastrointestinal motility2. The pathogenesis of 
IBD is considered to be multidimensional and multifactorial, involving genetic and environmental factors. The 
microbiota (microbial community assemblage) plays a critical role in the GI tract and is involved in nutrient 
digestion, vitamin synthesis, and promotion of mucosal immune tolerance. Perturbation of the intestinal micro-
biota composition and inflammatory response can aggravate intestinal barrier dysfunction and is a risk factor for 
IBD, although the mechanisms of IBD pathogenesis remain unclear. While various pharmaceutical treatments are 
available for IBD3, some therapeutic agents have a higher risk of toxicity and infectious complications4. Recently, 
microbiota control using faecal microbiota transplantation, probiotics, and prebiotics has been proposed as a new 
therapeutic option5.
Melatonin (N-acetyl-5-methoxy5 tryptamine) is a pineal gland hormone that regulates other hormones, circa-
dian rhythm, and oxidative stress6. Recent experiments have shown that melatonin also acts as an immune system 
modulator7 and ameliorates DSS colitis in mice8,9. Numerous studies have indicated that melatonin affects the 
permeability, motility, and barrier function of the intestine10,11. Melatonin treatment can improve GI tract diseases, 
such as irritable bowel syndrome12, IBD13, and necrotizing enterocolitis14, suggesting it has a critical role in the 
physiologic function of the GI tract. Interestingly, melatonin accumulates in the GI tract independent of produc-
tion from the pineal gland. The concentration of melatonin in the GI tract is 400-fold greater than that in the pineal 
gland15. The GI tract is also the largest source of enzymes for melatonin production16, and melatonin receptors are 
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highly expressed in the GI tract, suggesting that melatonin affects the immune response and the microbiota. Recent 
studies reported that melatonin increases the ratio of Firmicutes to Bacteroidetes and Akkermania10 and suppresses 
pathogenic bacteria17 in the intestine. Despite this knowledge, the pivotal signal pathway for the anti-colitic effect 
of melatonin and the exact mechanism for control of the intestinal microbiota remains unknown.
We previously reported that melatonin improves sleep deprivation-induced colitis in mice13. In this study, we 
investigate the involvement of Toll-like receptor (TLR) 4 signal in the action of melatonin. TLR4 is an important 
TLR that recognizes pathogen-associated molecular patterns18, especially Gram-negative bacteria, and controls 
intestinal epithelial cells and the mucosal barrier. We also explored the effects on microbiota dysbiosis and anti-
microbial peptide (AMP) regulation of melatonin in colitis.
Results
Intraperitoneal administration of melatonin ameliorates DSS-induced colitis through TLR4 sig-
nalling. TLR responses in intestinal epithelium by commensal bacteria play a significant role in the innate 
immunity, colonic homeostasis, and tolerance that link luminal bacteria and intestinal inflammation19. Among 
these TLRs, TLR4 recognize lipopolysaccharide (LPS) in particular and is primarily involved in control of Gram-
negative bacteria; an association between genetic polymorphisms of TLR4 and IBD have been reported, although 
some controversy remains19. TLR4 knockout (KO) mice are highly susceptible to Gram-negative bacteria20,21. Thus, 
to explore the involvement of TLR4 signalling in the anti-colitic effects of melatonin in vivo, colitis was induced in 
8-week-old wild type (WT) and TLR4 KO mice by administration of 2.5% dextran sulfate sodium (DSS) in drink-
ing water and intraperitoneal (i.p.) treatment with melatonin (Mel) or vehicle (Veh). Body weight changes were 
monitored daily. DSS-treatment for 10 days significantly increased body weight loss in the vehicle-treated group 
of both wild type and TLR4 KO mice. Although there were no significant differences in body weights between 
DSS + Veh and DSS + Mel groups (Fig. S1a,b), melatonin improved the disease activity index (DAI) (Fig. 1a,b) and 
attenuated shortening of the colon (Fig. 1c,d) only in wild type mice but not in TLR4 KO mice.
Defects of TLR4 signalling abolishes induction of goblet cells and anti-inflammatory response 
caused by melatonin. Colons of the DSS-treated group indicated severe inflammation with inflammatory 
cell infiltration and microscopic damage including transmural injury, crypt and epithelium loss, and goblet cell 
loss. In contrast, the melatonin-treated group of wild type mice showed significant improvement in histopatho-
logic features compared to the vehicle-treated group, while these effects were not observed in TLR4 KO mice 
(Fig. 1e–h). Of note, periodic acid-Schiff (PAS) staining indicated that the melatonin-treated control group dis-
played drastically increased goblet cells in colons, whereas TLR4 KO mice showed a trend toward decreased 
goblet cells compared to WT mice (Fig. 1e,f,i,j).
Colitis is characterized by expression of both pro-inflammatory cytokines, including tumour necrosis 
factor-alpha (Tnfa), interleukin 1-β (Il1b), and interleukin 17 A (Il17a), and anti-inflammatory cytokines, includ-
ing interleukin 10 (Il10) and interleukin 22 (Il22). Gene expression of these cytokines in colons was investigated. 
Real-time quantitative reverse-transcription polymerase chain reaction (qRT-PCR) analysis indicated that mel-
atonin significantly suppressed induction of Il1b and Il17a in WT mice, which was not true in TLR4 KO mice 
(Fig. 2a). Of note, TLR4 KO mice showed a trend of increased Tnfa, Il1b, and Il17a but reduced Il10 compared to 
WT mice (Fig. 2a,b). Taken together, these results indicate that melatonin modulates goblet cell differentiation 
and expression of inflammatory cytokines via TLR4 signalling.
Melatonin alter microbiota composition and corrects gut dysbiosis. There are two different recep-
tors for melatonin, type 1 A (MT1) and type 1B (MT2), which are encoded by Mtnr1a and Mtnr1b, respectively22 
and expressed in the intestine23–25. Expression of melatonin receptors (Mtnr1a and Mtnr1b) was assessed to inves-
tigate changes in melatonin and TLR4 signalling. qRT-PCR showed significantly increased expression of Mtnr1a 
and an increasing trend of Mtnr1b in colons of melatonin-administered mice compared to vehicle-treated groups 
when also treated with DSS (Fig. 2c). However, expression levels of Mtnr1a showed a decreased trend in TLR4 
KO mice compared to WT mice. Immunohistochemistry staining for MT1 in colon sections also supported these 
results (Fig. 2d–f). TLR4 is an important signal pathway in homeostasis between hosts and pathogens. The results 
indicate that melatonin signalling is linked to TLR4 signalling and affects the microbiota, and there is a critical 
modulator dependent on TLR4 signalling.
First, to observe changes in microbiota caused by melatonin, metagenome analysis was performed using fae-
ces of WT and TLR4 KO mice. 16 S rRNA gene high-throughput pyrosequencing revealed the overall microbi-
ome composition (beta diversity) assessed using principal coordinate analysis (PCoA), which showed distinct 
differences in clustering between the microbiomes of vehicle- and melatonin-treated groups and between WT 
and TLR4 KO mice (Fig. 3a). In alpha-diversity analysis, the melatonin-administered group showed signifi-
cantly increased richness of faecal microbiota assessed using Chao index (Fig. 3b), increasing trends in ACE 
and Shannon diversity index, and a decreased trend of Simpson index compared to DSS + Veh groups (Fig. S2a), 
indicating that melatonin increased richness and diversity of the microbiome. Of note, melatonin-treated 
groups showed significant suppression of Proteobacteria, a representative Gram-negative phylum that includes 
Salmonella and Escherichi coli (Fig. 3c), and increased Ruminococcaceae family strains (Fig. S2d), which represent 
butyrate-producing Gram-positive bacteria decreased in abundance in IBD fecal microbiota26,27. While the differ-
ence was not significant, melatonin-treated groups showed a decreasing trend in Bacteroidetes and an increasing 
trend of Firmicutes relative abundance compared to vehicle-treated groups (Fig. 3c) as previous studies17,28. A 
significantly decreased Firmicutes to Bacteroidetes ratio in DSS-treated groups was also shown in TLR4 KO mice, 
whereas a significantly decreased abundance of Proteobacteria was shown in DSS-treated groups of WT mice 
(Figs. 3c,d and S2b–f).
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Melatonin controls Gram-negative bacteria through induction of Reg3β. Next, gene expression 
related to AMPs in the proximal colon was examined, including cathelin-related antimicrobial peptide (Cramp), 
regenerating islet-derived protein 3 beta (Reg3b), defensin alpha 3 (Defa3), and defensin alpha 4 (Defa4), to 
explore the mechanism of microbiota regulation in the colon. Among these AMPs, only Reg3b expression was sig-
nificantly increased in melatonin-administered groups compared to other groups, in which Reg3b expression was 
undetectable. Expression of other intestinal antimicrobial molecules was not affected (Fig. 4a,b). In concordance, 
protein levels assessed by immunostaining and western blot were also increased in the melatonin-administered 
groups (Fig. 4c–g). However, TLR4 KO mice showed reduced levels of inducible AMPs, such as Reg3β and defen-
sins. This suggests that melatonin induces expression of AMPs, in particular Reg3β, through TLR4 signalling.
Reg3β can be induced in goblet cells29, and melatonin promotes goblet cells and modulates cytokines. 
Moreover, since melatonin can modulate the function of macrophages30, HT-29 cells were treated with mela-
tonin with or without THP-1 cells that were differentiated to macrophages by PMA stimulation and Alcian blue 
stain was performed to assess whether melatonin induced goblet cell differentiation in vitro. Melatonin treat-
ment increased Alcian blue staining compared to the vehicle-treated group. However, there was no difference 
between HT-29 only (Fig. 5a) and co-culture with differentiated THP-1 cells (Fig. S4a). The increased Alcian blue 
stain was not detected when cells were treated with TLR4 inhibitor. Consistently, mRNA expression of MUC2, 
MTNR1A, and MTNR1B significantly increased after melatonin and LPS treatment, a finding that was eliminated 
when treated with TLR4 inhibitor (Fig. 5b,c). These results suggest that melatonin directly modulates goblet 
Figure 1. Intraperitoneal administration of melatonin ameliorates DSS-induced colitis through TLR4 signal 
pathway. Wild type (WT) and TLR4 knockout (TLR4 KO) mice were administered 2.5% DSS in drinking water 
and treated i.p. with 0.25% EtOH/PBS (Veh) or melatonin (Mel, 10 mg/kg/day) from days 1 to 8. (a,b) Disease 
activity index (DAI). (c,d) Colon length. (e–j) Histopathology of colon. (e,f) Representative image of periodic 
acid-Schiff (PAS)-stain. (g,h) Histopathologic score. (i,j) Goblet cell score. Data represent mean ± S.E.M. 
(n = 10). Statistical significance was assessed using one-way ANOVA followed by Dunnett post-test compared 
to DSS + Veh. *P < 0.05, **P < 0.01, ***P < 0.005, ##P < 0.01 vs. TLR4 KO, ###P < 0.005 vs. TLR4 KO. Con, 
untreated control.
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cell differentiation, which requires a melatonin receptor and the TLR4 signal pathway. In addition, melatonin 
increased mRNA expression of a proinflammatory cytokine (TNFA) and an anti-inflammatory cytokine (IL10) 
as well as melatonin receptors (MTNR1A, MTNR1B) in differentiated THP-1 cells (Fig. 5e,f).
Upregulated expression of REG3G, CAMP, and DEFA3, the human orthologues of Reg3b, Cramp, and Defa3, 
in HT-29 cells was observed after melatonin only treatment or melatonin co-treatment with LPS (Fig. 5d), 
although induction of Cramp and Defa3 was not induced by melatonin in vivo. Consistently, we observed upreg-
ulated expression of REG3G in differentiated THP-1 cells (Fig. 5g). To confirm that melatonin-treated cells sup-
press growth of Gram-negative bacteria in the pathogenesis of colitis, culture media of HT-29 cells or HT-29 cells 
co-cultured with differentiated THP-1 cells were treated with Escherichia coli, a representative Gram-negative 
bacterium. Dots of colonies and optical density of E. coli culture revealed that both melatonin-treated HT-29 cells 
and co-culture with THP-1 cells inhibited growth of E. coli, which was not affected by co-culture with THP-1 
cells (Figs. 5h,i and S4b). These results suggest that melatonin suppresses Bacteroidetes through Reg3β induction.
Melatonin promotes wound healing in intestinal epithelial cells through TLR4 signal-
ling. Previous studies have reported that TLR4 signalling promotes wound healing and induces AMPs in 
intestines31. Moreover, expression of melatonin receptor is upregulated by melatonin through TLR4 signalling. 
To assess whether melatonin affects intestinal barrier regulation through wound repair, a wound healing assay 
was performed using scraped HT-29 cells with or without differentiated THP-1 cells. Melatonin promoted wound 
closure compared to the control, which was further increased by LPS stimulation. However, there was no signif-
icant difference between HT-29 cells only (Fig. 6a,b) and HT-29 cells co-cultured with THP-1 cells (Fig. S4c,d), 
suggesting that melatonin directly affects wound healing of IECs.
Discussion
Melatonin has versatile functions, including antioxidant, memory formation, and blood pressure reduction qualities32. 
Additionally, many previous studies showed that oral and rectal administration of melatonin suppresses DSS-induced 
colitis33–35. Melatonin is abundant in the gut15, and pinealectomy has no influence on gut melatonin concentrations36. 
Although it is widely accepted that IBD involves perturbation of homeostasis between the gut microbiota and the 
host immune system37, the effects of melatonin on dysbiosis in IBD remain unknown. It is not yet clear how mela-
tonin shapes biological functions, although recent studies have suggested that melatonin alters the microbiome of 
the GI tract10,17. Herein, we showed that melatonin i.p. administration in WT mice alleviates DSS-induced colitis. As 
with the previously reported effect of melatonin on DSS- or TNBS-induced colitis38,39, melatonin suppresses potent 
pro-inflammatory mediators in colitis such as Il1b and Il17a, and controls microbiota in the intestine.
Figure 2. Melatonin modulates inflammatory cytokines and melatonin receptors in the colon through TLR4 
signal pathway. (a–c) Gene expression in colon tissues. mRNA expression of pro-inflammatory cytokines (Tnfa, 
Il1b, Il17a) (a), anti-inflammatory cytokines (Il10, Il22) (b), and melatonin receptors (Mtnr1a, Mtnr1b) (c) were 
evaluated by quantitative RT-PCR. (d–f) Protein levels of melatonin receptors in colon tissues from WT (d) and 
TLR4 KO (e) mice. (d,e) Representative image of immunohistochemistry for melatonin receptor 1 A (MTNR1A). 
(f) Densitometric analysis. Data represent mean ± S.E.M. (n = 7). Statistical significance was assessed using Student’s 
t-test. *P < 0.05, **P < 0.01, ***P < 0.005, #P < 0.05 vs. TLR4 KO, ###P < 0.005 vs. TLR4 KO. Con, untreated control; 
Mel, melatonin-treated; TLR4 KO, TLR4 knockout mice; Veh, vehicle-treated; WT, wild-type mice.
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Consistent with our observation, many studies have reported that melatonin increases goblet cells in the 
intestine of vertebrates10,17,39,40. Goblet cells are important secretory IECs in colitis19 that produce mucin and 
AMPs. These products serve as the first lines of defence against pathogens by maintaining homeostasis of the 
mucus barrier and commensal bacteria and by segregating intestinal bacteria and the epithelium41. Considering 
that IECs interact with enteric bacteria, AMP production from IECs may affect the composition and abundance 
of the microbiota and play a role in protecting against bacterial invasion42, in addition to other types of cells 
such as T cell and innate lymphoid cells43. Although the route of administration was different from the previous 
study, we still identified indications that melatonin can reverse microbial dysbiosis in colitis and increase the 
Firmicutes to Bacteroidetes ratio. While melatonin has been reported to elevate the abundance of Firmicutes such 
as Lactobacillus and Akkermania, and reduce Bacteroidetes such as Prevotellaceae10,17, we did not observe any 
significant changes in these bacteria. This is likely due to different bacterial niches within the GI tract caused 
by the different sampling method. Given that mucin affects the composition of microbiota29 and some bacteria 
use glycan as a nutrient44,45, microbiota modulation by melatonin may be due to mucin regulation by goblet cell 
differentiation.
More importantly, host defences against Gram-negative bacteria such as Salmonella can be controlled by 
AMPs such as Reg3β and defensin alpha46–48. This may be another important mechanism of microbial control by 
melatonin. LPS in the cell walls of Gram-negative bacteria, pathogens commonly associated with IBD, induces an 
inflammatory response through TLR449. TLR4 is receptor for bacterial LPS and regulates LPS-induced inflamma-
tory response. Gram-negative bacteria abundantly increase in TLR4 KO mice, and TLR4 induces differentiation 
of goblet cells and AMP expression, including Reg3γ and Reg3β42,50. We found Gram-negative bacteria such as 
Proteobacteria are elevated in the feces of TLR4 KI mice (Fig. 3c), while Firmicutes such as Ruminococcaceae 
are reduced in those of TLR4 KI mice (Fig. S2d). As in the previous study29,48, we identified that Reg3β can be 
induced in proximal colon tissue. The previous study reported that melatonin inhibited infection in an enter-
otoxigenic E. coli-infected model17. Our study is the first to show that melatonin increased AMPs, especially 
Reg3β. Consistent with the antibacterial specificity of Reg3β for Gram-negative bacteria47,51,52,46, we observed 
dramatically increased Reg3β expression in mouse colons, IECs, and macrophages and suppressed growth of E. 
coli when IECs were treated with melatonin. Our results suggest that induction of AMPs by melatonin is a direct 
cause of Gram-negative bacterial suppression. Indeed, Reg3β deficient mice show abnormalities in inhibiting 
Gram-negative bacteria such as Salmonella47,53. AMPs are always expressed, but Reg3β is known to be expressed 
by TLR activation during microbial growth or inflammation46,54. Given normal physiologic conditions, the colon 
does not express Reg3β and α-defensin but these AMPs are induced in colitis55, suggesting that TLR4 signalling 
Figure 3. Melatonin suppresses dysbiosis of gut microbiome through TLR4 signal pathway. Fecal microbiome 
composition was generated using 16 S rRNA sequencing, and beta and alpha diversity and taxa were analysed.  
(a) Principal coordinate analysis (PCoA). (b) Chao1 index. (c) Microbiota profiles in phylum level. (d) Firmicutes 
to Bacteroidetes ratio. Data represent mean ± S.E.M. (n = 5). Statistical significance was assessed using Student’s 
t-test (b,d) and one-way ANOVA followed by Dunnett post-test (c). *P < 0.05, **P < 0.01. Con, untreated 
control; Mel, melatonin-treated; OUT, operational taxonomic unit; TLR4 KO, TLR4 knockout mice; Veh, 
vehicle-treated; WT, wild-type mice.
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also plays a role in Reg3β regulation by melatonin. Although melatonin has been reported to inhibit TLR4/NF-κB 
signalling56,57, TLR4 signalling appears to link pathogen sensing and AMP production is thought to play protec-
tive role in melatonin function. Experiments with TLR4 KO mice and TLR4 inhibitor revealed the anti-colitic 
effects of melatonin on goblet cell differentiation and induction of melatonin receptor. We demonstrated previ-
ously that TLR4 signalling is required to goblet cell differentiation58.
Reg3β expression also was dependent on TLR4 signalling despite a contradictory study that melatonin sup-
pressed related TLR4 signalling56. TLR4 mediates healing and proliferation of the injured intestinal epithelium31,40 
and subsequently regulates intestinal barrier function and mucosal healing59. Consistently, we found increased 
wound healing of IECs with melatonin, and these effects require TLR4 signalling and are mediated through mac-
rophages. We also observed synergetic expression of mucin, antimicrobial peptides, and melatonin receptors after 
melatonin treatment with LPS, which is likely due to increased expression of TLR4 by LPS. Our results are also 
consistent with those of a previous study that TLR4 KO mice are more susceptible to colitis than WT mice60,61. 
Nevertheless, there may be other pathways for melatonin function than TLR4, and further mechanical study is 
needed to explain these contradictory results of the interaction between melatonin and TLR4 signalling.
Although further study such as conventional knock-out system is also required to confirm the exact mech-
anisms of AMP induction by melatonin and to exclude many confounding factors, this is the first study to 
explain how melatonin regulates the microbiota in colitis and to show a link between melatonin and microbiota. 
Additionally, we showed that bacterial sensing through TLR4, mucin, and Reg3β production by goblet cells was 
involved in the anti-colitic effects of melatonin, suggesting that melatonin may be useful in microbiota control 
and therapeutics for IBD.
Figure 4. Melatonin promotes production of antimicrobial peptides through TLR4 signal pathway. (a,b) Gene 
expression of antimicrobial peptides in colon tissues. mRNA levels of Cramp, Reg3b, Defa3, and Defa4 in WT 
(a) and TLR4 KO (b) mice were evaluated by quantitative RT-PCR. (c–e) Protein levels of Reg3β in colon tissues 
from WT and TLR4 KO mice. (c,d) Representative image of immunofluorescence stain for Reg3β in colons 
of WT (c) and TLR4 KO (d) mice. Red arrows indicate representative goblet cells. (e) Densitometric analysis 
of immunofluorescence stain. Data represent mean ± S.E.M. (n = 7). (f) Representative image of western blot 
for Reg3β in colon lysates of WT and TLR4 KO mice. (e) Densitometric analysis of western blot. Statistical 
significance was assessed using Student’s t-test. *P < 0.05, **P < 0.01, ***P < 0.005, ##P < 0.01 vs. TLR4 KO. 
Con or C, untreated control; DSS or D, DSS-treated; Mel or M, melatonin-treated; TLR4 KO, TLR4 knockout 
mice; Veh or V, vehicle-treated; WT, wild-type mice.
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Methods
Mouse colitis model. TLR4-deficient BALB/c mice were provided by the Korea Research Institute of 
Bioscience and Biotechnology (Daejon, South Korea) and were bred as previously described58. To induce acute coli-
tis, 8-9-week-old male BALB/c mice and TLR4 knockout mice were fed 2.5% (w/v) DSS (MW 36,000–50,000, MP 
Biomedicals, Solon, OH, USA) in their drinking water for 6 days. The first day of DSS administration was designated 
Figure 5. Melatonin controls Gram-negative bacteria by goblet cell differentiation and antimicrobial peptide 
production through TLR4 signal pathway. (a–d) HT-29 cells were treated with vehicle (Veh) or melatonin 
(Mel) with or without TLR4 inhibitor (T4I) for 48 h. (a) Representative image of Alcian blue stain (left) and 
densitometry analysis (right). (b–d) Gene expressions of melatonin receptor, mucin, and antimicrobial peptides 
in intestinal epithelial cells (IECs). mRNA levels of mucin 2 (MUC2) (b), melatonin receptor (MTNR1A, 
MTNR1B) (c), and antimicrobial peptides (REG3B, CAMP, DEFA3) (d) were evaluated by quantitative RT-
PCR. Data represent means ± S.E.M. of 3 independent experiments. (e–g) The differentiated THP-1 cells 
were treated with vehicle or melatonin with or without TLR4 inhibitor for 4 h. mRNA levels of cytokines 
(TNFA, IL10) (e), melatonin receptor (MTNR1A, MTNR1B) (f), and antimicrobial peptides (REG3B) (g) 
were evaluated by quantitative RT-PCR. (h,i) Antimicrobial activity of melatonin-treated cells. Escherichia 
coli (OD600 = 0.5) grown in LB broth were treated with culture media from HT-29 cells, incubated for 48 h, 
diluted at 1/105, and seeded on agar plate. (h) Representative image of colonies on agar plate. Diluted bacterial 
cultures in the presence of HT-29 culture media were spot-inoculated onto EMB agar plate and captured in Gel 
document system. (i) Optical density (OD600) of E. coli culture. Data represent mean ± S.E.M. of 4 independent 
experiments. Statistical significance was assessed using one-way ANOVA followed by Dunnett post-test. 
*P < 0.05, **P < 0.01, ***P < 0.005, #P < 0.05 vs. DMSO, ##P < 0.01 vs. DMSO, ###P < 0.005 vs. DMSO. DMSO, 
dimethyl sulfoxide-treated; LPS, lipopolysaccharide-treated, Mel, melatonin-treated; T4I, CLI-095-treated; Veh, 
vehicle-treated.
Figure 6. Melatonin improves wound healing of intestinal epithelial cells through TLR4 signal pathway. (a) 
Representative image of wound healing assay. (b) Wound closure rate. Wound closure rate was assessed by 
measuring wound area using Image J software. Data represent mean ± S.E.M. of 3 independent experiments. 
Statistical significance was assessed using one-way ANOVA followed by Dunnett post-test. *P < 0.05, 
**P < 0.01, ##P < 0.01 vs. DMSO. DMSO, dimethyl sulfoxide-treated; LPS, lipopolysaccharide-treated, Mel, 
melatonin-treated; T4I, TLR4 inhibitor-treated; Veh, vehicle-treated.
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day 0; drinking water with DSS was replaced with normal drinking water on day 6. Mice were randomly divided 
into four groups: control, melatonin, DSS + vehicle, and DSS + melatonin. Control and melatonin group mice were 
administered only drinking water. Melatonin and DSS + melatonin groups received melatonin (10 mg/kg/day) by 
i.p. from days 1 to 8, while Control and DSS + vehicle groups were treated with 0.25% EtOH/PBS i.p based on our 
previous studies using DSS-induced colitis to detect rapid response8,13,62. All mice were sacrificed on day 9, and 
colon length was measured. Colons and cecal contents were collected for analysis. All mice were monitored daily 
for body weight loss, stool consistency, and rectal bleeding. Disease activity index (DAI) scores were evaluated 
before sacrifice. DAI score was calculated based on the following parameters: body weight loss (0, none; 1, 1–5%; 2, 
5–10%; 3, 10–20%; 4, >20%), rectal bleeding (0, absence; 1 and 2, light bleeding; 3, bleeding), and stool consistency 
(0, negative; 1 and 2, loose; 3, diarrhoea). DAI scores were expressed as the average of these three parameters. All 
animals were kept under standard conditions at 21–22 °C under a 12-h light/dark cycle. A longitudinal incision was 
made along the entire colon, and all stool was eliminated by washing with PBS. Parts of the proximal colon were cut 
into 3 pieces for PAS staining and RNA isolation. All experiments using animals were reviewed and approved by 
the Institutional Animal Care and Use Committee (IACUC) of Yonsei University Severance Hospital, Seoul, Korea 
(IACUC Approval No: 2015-0407) and were conducted in accordance with the guidelines of the IACUC.
Periodic acid-Schiff and Alcian blue staining, immunostaining, and histology. Four-µm-thick 
paraffin sections of the distal colon of each animal or of cells were stained with PAS stain or Alcian blue, respec-
tively, according to standard procedures to evaluate the histopathology and goblet cells. Immunohistochemistry 
was performed using anti-mouse MTNR1A (1:500; Abcam, Cambridge, MA, USA), as previously described58,63. 
After incubation with anti-mouse Reg3β (1:200, R&D Systems, Minneapolis, MN, USA), sections were incubated 
with Alexa Fluor-488-conjugated secondary antibodies (Thermo Fisher Scientific, San Jose, CA, USA) for immu-
nofluorescence stains. All images were obtained by confocal microscopy (Carl Zeiss LSM 700, Prenzlauer, Berlin, 
Germany), and staining intensity was determined using Image J software (NIH, Bethesda, MD, USA). Goblet cell 
staining was scored from 0 to 5 (5, minimal, <10%; 4, minimal, <20%; 3, mild, 21–30%; 2, moderate, 31–40%; 1, 
moderate, 41–50%; 0, marked, >50%).
cell culture and treatment. HT-29 (Korea Cell Line Bank, Seoul, South Korea) and THP-1 (ATCC, 
Manassas, VA, USA) cell lines were maintained in 10% foetal bovine serum-supplemented RPMI medium 
with or without antibiotics at 37 °C in a humidified atmosphere of 5% CO2 with or without melatonin (200 µM, 
Sigma-Aldrich, St. Louis, MO, USA), lipopolysaccharides (LPS, 200 ng/mL, Sigma-Aldrich, St. Louis, MO, USA), 
and TLR4 inhibitor CLI-095 (1 μg/mL, InvivoGen, San Diego, CA, USA) for the indicated times. THP‐1 cells 
were treated with a final 100 nM of phorbol 12‐myristate 13‐acetate (PMA, Sigma–Aldrich) to differentiate into 
macrophage‐like cells.
The indigenous E. coli strain previously isolated from mouse64 was kindly provided by Yoon. Bacterial cul-
ture incubated with HT-29 cell culture media was plated onto nutrient agar or EMB agar or cultured in nutrient 
broth at 37 °C for 48 h under static culture conditions. E. coli colony images were captured by a Gel document 
system (MINIBIS PRO, Jerusalem, Israel), and the optical density (OD600) of E. coli culture was measured using 
ELISA reader VERSA Max (Molecular Devices, Sunnyvale, CA, USA) and analysed using SoftMax Pro ver.6.3 
(Molecular Devices).
Real-time quantitative reverse-transcription polymerase chain reaction (Rt-pcR). Total 
RNA was prepared from colon tissues and cells using a Ribospin kit (Geneall, Seoul, Korea) and TRIzol 
Reagent (Life Technologies, Carlsbad, CA, USA), respectively, as per the manufacturer’s instructions. RNA 
was reverse-transcribed using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster 
City, CA). The mRNA expression levels were quantified using a StepOne Plus real-time PCR system (Applied 
Biosystems) and SYBR Green Master Mix (Applied Biosystems). Thermal cycles were: 45 cycles of 95 °C for 30 s, 
60–63 °C for 30 s, and 72 °C for 40 s. All PCRs were run in duplicate. The results were normalized to expression of 
the β-actin gene, and the relative expression of each target mRNA was calculated as 2−ΔCt. Results were normal-
ized to expression of β-actin and were calculated by the equation 2−ΔΔCt. Primer sequences were synthesized by 
Macrogen (Seoul, Korea). PCR primers are listed in Table S1.
Metagenome analysis of microbiome. Bacterial genomic DNA was obtained from faeces using a 
FastDNA™ SPIN for Soil Kit (MP Biomedicals, Santa Ana, CA, USA) according to the manufacturer’s instructions. 
Microbiome detection using bar-coded primers flanking the V3-V4 region of the 16S rRNA gene was completed by 
ChunLab Inc. (Seoul, Korea). Operational taxonomic units (OTUs) were identified based on 16 S rRNA sequence 
data using the EzTaxon-e database (http://eztaxon-e.ezbiocloud. net). Principal coordinate analysis (PCoA) of gut 
microbiome composition was assessed by Jensen-Shannon. OTU richness (abundance-based coverage estimator 
(ACE) and Chao1 indices) and diversity (Shannon index and Simpson index) were analysed for alpha diversity anal-
ysis. Bacterial community abundance and composition were analysed using CLcommunity software (Chunlab Inc.).
Western blot analysis. Colon tissues were lysis harvested on ice by washing twice with cold PBS, scraping, 
and resuspending. The protein concentration of colon lysate was determined using the BCA assay with bovine 
serum albumin. Protein samples prepared by mixing SDS sample buffer were run on NuPAGE 4–12% gradi-
ent Bis-Tris and electrotransferred to a polyvinylidene difluoride membrane (Thermo Fisher Scientific) as in a 
previous study.64 Blots were blocked with 5% (w/v) skim milk in Tris-buffered saline solution containing 0.1% 
Tween 20 (Pierce, Appleton, WI, USA) and incubated overnight at 4 °C with antibodies against Reg3β (1:1000, 
R&D Systems) and β-actin (Sigma). Blots were additionally incubated with secondary antibodies conjugated with 
horseradish peroxidase for 1 hour at room temperature and visualized with ELC Prime detection reagent and the 
LAS 4000 Mini apparatus (GE Healthcare, Piscataway, NJ, USA).
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Statistical analysis. GraphPad Software (La Jolla, CA, USA) was used for statistical analyses. The sig-
nificance of differences between conditions was assessed using Student’s t-test or one-way analysis of variance 
(ANOVA). P values < 0.05 were considered significant.
Received: 20 September 2019; Accepted: 14 January 2020;
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